Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01343355
Recruitment Status : Unknown
Verified July 2011 by St. Marianna University School of Medicine. Recruitment status was: Active, not recruiting
An open-label, non-randomised, uncontrolled, proof-of-concept study of patients with HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Participants will receive oral administration of tamibarotene in the amount of 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks. The patients will be followed up for further 8 weeks. Efficacy will be monitored by measuring clinical scores including motor and urination function, HTLV-1 proviral load, immunological parameters, and markers in the spinal fluid. Safety will be evaluated at the same time.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
30 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who have been diagnosed as HAM according to the WHO criteria
Patients who are positive for HTLV-I antibody in the spinal fluid
Patients, if female, who are not pregnant or breastfeeding, either agreed to take contraceptive measures during and two years after the treatment, or sterile
Patients, if male, who agreed to take contraceptive measures during and six months after the treatment
Patients who have been informed and understood the contents of the study and consented to participate in the signed form.
Patients who has a rapid progress in the symptoms defined as an increase of two or more in Osame's Motor Disability Score for HAM patients in the past one year.
Patients of hyperlipidemia (serum triglyceride higher than 400 mg/dL)
Patients who were administered new or increased dose of corticosteroid in the past 8 weeks before the intervention
Patients who received steroid pulse therapy in the past 8 weeks before the intervention
Patients who were administered new or increased dose of immunosuppressant in the past 8 weeks before the intervention
Patients with a history of serious drug allergy
Patients with significant complication such as malignancy, severe heart failure, and other serious diseases.
Patients who were in the past administered etretinate.